Altimmune
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
910 Clopper Rd Ste 201S, Gaithersburg, M...Phone Number
(240) 654-1450Website
www.altimmune.comRevenue
<$5 MillionStock Symbol
ALTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Altimmune
Altimmune is a late clinical-stage biotechnology company focused on developing innovative therapies for serious liver, metabolic, and obesity-related diseases, with a primary emphasis on advancing its lead drug candidate, pemvidutide, which is designed to target key biological pathways involved in these conditions, while leveraging scientific research and clinical trials to create effective treatments that address unmet medical needs and improve patient outcomes through novel therapeutic approaches in the healthcare sector.Explore more
Altimmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Altimmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Altimmune
Funding: Get notified immidiatlly once Altimmune has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Altimmune recently announced quarterly report
Product Launch: Get notified when Altimmune launches new products
Check if Altimmune has recently received funding, and reach out quickly before it becomes old news!
Check out if Altimmune is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Altimmune had a recent Job posting/layoffs
Altimmune, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Altimmune
Compare insights from companies similar to Altimmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Altimmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Altimmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Altimmune.
Altimmune financials insights
Gather financial insights about Altimmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Multiple Rounds
$66M
2020
Debt
$350K
Grant
$4.7M
2026
Unspecified
$225M
Altimmune Tech Stack
A closer look at the technologies used by Altimmune
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Project
Altimmune is conducting the global PERFORMA Phase III trial of pemvidutide in MASH across approximately 300 sites, with one-third located in the US and two-thirds outside the US, working closely with its contract research organization (CRO) on site activation across multiple countries.
Clinical Operations
Project
Clinical Operations
Altimmune News & Media
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.Altimmune Q2 Earnings Call Highlights
Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD. Chairman and Chief Executive OfficeAltimmune Announces Second Quarter 2026 Financial Results and Business Update
Initiated global PERFORMA Phase 3 trial in MASHAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Altimmune
Sign Up For FreeTo access detailed company insights
Altimmune is a late clinical-stage biotechnology company focused on developing innovative therapies for serious liver, metabolic, and obesity-related diseases, with a primary emphasis on advancing its lead drug candidate, pemvidutide, which is designed to target key biological pathways involved in these conditions, while leveraging scientific resea... Read More
